Improvement of tumor oxygenation by mild hyperthermia.
There is now abundant evidence that oxygenation in rodent, canine and human tumors is improved during and for up to 1-2 days after heating at mild temperatures. An increase in tumor blood perfusion along with a decline in the oxygen consumption rate appears to account for the improvement of tumor oxygenation by mild hyperthermia. The magnitude of the increase in tumor pO(2), determined with oxygen-sensitive microelectrodes, caused by mild hyperthermia is less than that caused by carbogen breathing. However, mild hyperthermia is far more effective than carbogen breathing in increasing the radiation response of experimental tumors, probably because mild hyperthermia oxygenates both (diffusion-limited) chronically hypoxic and (perfusion-limited) acutely hypoxic cells, whereas carbogen breathing oxygenates only the chronically hypoxic cells. Mild hyperthermia is also more effective than nicotinamide, which is known to oxygenate acutely hypoxic cells, in enhancing the radiation response of experimental tumors. The combination of mild hyperthermia with carbogen or nicotinamide is highly effective in reducing the hypoxic cell fraction in tumors and increasing the radiation response of experimental tumors. A primary rationale for the use of hyperthermia in combination with radiotherapy has been that hyperthermia is equally cytotoxic toward fully oxygenated and hypoxic cells and that it directly sensitizes both fully oxygenated and hypoxic cells to radiation. Such cytotoxicity and such a radiosensitizing effect may be expected to be significant when the tumor temperature is elevated to at least 42-43 degrees C. Unfortunately, it is often impossible to uniformly raise the temperature of human tumors to this level using the hyperthermia devices currently available. However, it is relatively easy to raise the temperature of human tumors into the range of 39-42 degrees C, which is a temperature that can improve tumor oxygenation for up to 1-2 days. The potential usefulness of mild hyperthermia to enhance the response of human tumors to radiotherapy by improving tumor oxygenation merits continued investigation.
Song
C W
CW
Department of Therapeutic Radiology-Radiation Oncology, University of Minnesota Medical School, 420 Delaware Street SE, MMC 494, Minneapolis, MN 55455, USA.
Park
H
H
Griffin
R J
RJ
D000818:Animals; D002245:Carbon Dioxide / Q000494:pharmacology / Q000627:therapeutic use; D015687:Cell Hypoxia; D003131:Combined Modality Therapy; D004285:Dogs; D006801:Humans; D006979:Hyperthermia, Induced; D051379:Mice; D008809:Mice, Inbred C3H; D009369:Neoplasms / Q000378:metabolism / Q000532:radiotherapy / Q000628:therapy*; D009536:Niacinamide / Q000494:pharmacology / Q000627:therapeutic use; D010100:Oxygen / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D010313:Partial Pressure; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D012039:Regional Blood Flow; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use; D023041:Xenograft Model Antitumor Assays
D011838:Radiation-Sensitizing Agents; D014665:Vasodilator Agents; D002245:Carbon Dioxide; D009536:Niacinamide; C011700:carbogen; D010100:Oxygen